Relapsed/Refractory Follicular Lymphoma Clinical Trials in Nanjing, Jiangsu
2 recruitingNanjing, Jiangsu, China
Showing 1–2 of 2 trials
Recruiting
Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Marginal Zone LymphomaRelapsed/Refractory Follicular Lymphoma
BeiGene780 enrolled277 locationsNCT05100862
Recruiting
Phase 2
Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
Relapsed/Refractory Follicular Lymphoma
The First Affiliated Hospital with Nanjing Medical University33 enrolled1 locationNCT07418190